Angiomyogenesis with HIF-11 responsive microRNAs Summary: Stem cells promote functional recovery in experimental animal models and patients with myocardial infarction through multifactorial mechanisms. We hypothesize that stem cells reprogrammed with hypoxia inducible factor-11 (HIF-11) responsive microRNAs (HRMs) will promote angiomyogenesis in the infarcted heart. Ranging from maintenance of lineage commitment to angiogenic paracrine activity and differentiation potential, MicroRNAs (miRs) determine the inherent properties of stem cells which possess a discrete miRs profile. Hence, reprogramming of stem cells by manipulation of miRs can improve their paracrine activity and angiomyogenic potential. We have identified a number of HRMs which are down- or upregulated in mesenchymal stem cells (MSCs) during reprogramming by intermittent cycles of brief anoxia/re-oxygenation (A/R) in parallel with activation of HIF-11. The most significantly altered HRMs were miR-210 and miR-107 which markedly influenced the survival and angiogenic paracrine behavior of MSCs (Preliminary results). The overall goal of this proposal is to elucidate the mechanistic involvement of HRMs and their target genes during reprogramming which mediate stem cell functions of paracrine activity, angiomyogenic differentiation and survival. Our proposal is aimed to validate three hypotheses. Hypothesis-1: HRMs regulate angiogenic paracrine activity in stem cells.
The specific aims pertinent to hypothesis-1 will define the expression profile of the discrete set of HRMs in the reprogrammed MSCs (RePMSCs) with special emphasis on their angiogenic paracrine activity. Hypothesis-2: HRMs are mechanistic determinants of functional consequences of the reprogrammed stem cells. The relevant specific aim will involve in vitro models of angiogenesis and experimental animal model of acute coronary artery ligation to show that the reprogramming accentuate the angiogenic potential of stem cells with the mechanistic participation of HRMs. The end-points of in vivo studies will include blood vessel density analysis, maturation index and improved regional blood flow in the ischemic heart and preservation of global cardiac function. A comparison between RePMSCs engraftment and direct injection of HRMs to the ischemic heart will also be carried out. Hypothesis-3: HRMs mechanistically participate in stem cell survival. We have already shown that HRMs significantly improve stem cell survival. Our preliminary studies showed that 4 different anti-apoptotic genes were up-regulated in the stem cells treated with repeated cycles of A/R. We will elucidate the role of each one of the identified target genes of HRMs in stem cell survival. We will also establish that changes in HRMs in the infarcted heart after RePMSCs engraftment constitute an integral and novel mechanism of cardiac repair. Put together, we propose that stem cells reprogrammed by intermittent cycles of A/R with mechanistic involvement of HRMs, will promote their paracrine, angiomyogenic and cytoprotective responses in the infarcted heart. These studies will facilitate the development of novel therapeutic approaches based on manipulation of HRMs in donor stem cells.

Public Health Relevance

This proposal is designed to investigate angiomyogenic and paracrine behavior of stem cells reprogrammed by manipulation of HIF-11 responsive microRNAs (HRMs) using our novel approach of treating the cells with intermittent multiple short cycles of anoxia/reoxygenation. We anticipate improved angiomyogenic response in the infarcted heart after treatment with reprogrammed stem cells. Our proposal will be the first to elucidate the mechanistic participation of HRMs in paracrine behavior, angiomyogenic potential and cytoprotection.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Adhikari, Bishow B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Schools of Medicine
United States
Zip Code
Arif, Mohammed; Pandey, Raghav; Alam, Perwez et al. (2017) MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction in rodents. J Mol Med (Berl) 95:1369-1385
Waters, Renae; Pacelli, Settimio; Maloney, Ryan et al. (2016) Stem cell secretome-rich nanoclay hydrogel: a dual action therapy for cardiovascular regeneration. Nanoscale 8:7371-6
Pandey, Raghav; Yang, Yunhan; Jackson, Laeia et al. (2016) MicroRNAs regulating meis1 expression and inducing cardiomyocyte proliferation. Cardiovasc Regen Med 3:
Pandey, Raghav; Ahmed, Rafeeq P H (2015) MicroRNAs Inducing Proliferation of Quiescent Adult Cardiomyocytes. Cardiovasc Regen Med 2:
Buccini, Stephanie; Haider, Khawaja Husnain; Ahmed, Rafeeq P H et al. (2012) Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart. Basic Res Cardiol 107:301
Kim, Ha Won; Jiang, Shujia; Ashraf, Muhammad et al. (2012) Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function. J Mol Med (Berl) 90:997-1010
Lu, Gang; Jiang, Shujia; Ashraf, Muhammad et al. (2012) Subcellular preconditioning of stem cells: mito-Cx43 gene targeting is cytoprotective via shift of mitochondrial Bak and Bcl-xL balance. Regen Med 7:323-34
Lai, Vien Khach; Ashraf, Muhammad; Jiang, Shujia et al. (2012) MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 11:767-77
Lai, Vien Khach; Afzal, Muhammad Rizwan; Ashraf, Muhammad et al. (2012) Non-hypoxic stabilization of HIF-I? during coordinated interaction between Akt and angiopoietin-1 enhances endothelial commitment of bone marrow stem cells. J Mol Med (Berl) 90:719-30
Haider, Khawaja Husnain; Ashraf, Muhammad (2012) Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci 111:323-56

Showing the most recent 10 out of 18 publications